BridgeBio Pharma Cash And Short Term Investments Over Time
| BBIO Stock | USD 31.57 0.66 2.05% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out BridgeBio Pharma Performance and BridgeBio Pharma Correlation. BridgeBio |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Revenue Per Share | Quarterly Revenue Growth 2.371 | Return On Assets | Return On Equity |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Cash And Short Term Investments Analysis
Compare BridgeBio Pharma and related stocks such as IVERIC Bio, Blueprint Medicines Corp, and Amylyx Pharmaceuticals Cash And Short Term Investments Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPMC | 2 M | 2 M | 2 M | 2 M | 47.2 M | 162.7 M | 268.2 M | 673.4 M | 494 M | 548 M | 1.5 B | 1 B | 1.1 B | 710.6 M | 615.5 M | 658.6 M |
| DAWN | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 43.7 M | 284.3 M | 342.3 M | 366.3 M | 531.7 M | 292.5 M |
| TERN | 86.9 M | 86.9 M | 86.9 M | 86.9 M | 86.9 M | 86.9 M | 86.9 M | 86.9 M | 86.9 M | 19.6 M | 74.9 M | 166 M | 283.1 M | 263.4 M | 303 M | 163.9 M |
| APLS | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 13.6 M | 36 M | 24.9 M | 175.6 M | 176.3 M | 352 M | 877.6 M | 700.5 M | 551.8 M | 352.3 M | 411.3 M | 337 M |
| PTCT | 28.4 M | 28.4 M | 2.7 M | 142.5 M | 315.2 M | 338.9 M | 231.7 M | 191.2 M | 227.6 M | 686.6 M | 1.1 B | 773.4 M | 410.7 M | 876.7 M | 1.1 B | 1.2 B |
| KRYS | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 49.6 M | 111.8 M | 193.7 M | 271.3 M | 438.1 M | 379.2 M | 532.2 M | 597.5 M | 314.7 M |
| MDGL | 76.2 M | 39.7 M | 100.6 M | 91.5 M | 97.7 M | 66.6 M | 40.5 M | 191.5 M | 483.7 M | 439 M | 284.1 M | 270.3 M | 358.8 M | 634.1 M | 926.3 M | 972.6 M |
| ABOS | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 43.8 M | 194.2 M | 177.6 M | 243.5 M | 280.1 M | 146.5 M |
| INZY | 43.2 M | 43.2 M | 43.2 M | 43.2 M | 43.2 M | 43.2 M | 43.2 M | 43.2 M | 43.2 M | 47.1 M | 159.9 M | 111.8 M | 127.9 M | 188.6 M | 216.9 M | 124.4 M |
| XFOR | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 3 M | 76.8 M | 30.8 M | 126.2 M | 78.7 M | 81.8 M | 121.7 M | 114.2 M | 131.3 M | 78.2 M |
BridgeBio Pharma and related stocks such as IVERIC Bio, Blueprint Medicines Corp, and Amylyx Pharmaceuticals Cash And Short Term Investments description
Short Term Investments is an account in the current assets section of BridgeBio Pharma balance sheet. This account contains BridgeBio Pharma investments that will expire within one year. These investments include stocks and bonds that can be liquidated by BridgeBio Pharma fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.My Equities
My Current Equities and Potential Positions
| BridgeBio Pharma | BBIO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 30.03
Check out BridgeBio Pharma Performance and BridgeBio Pharma Correlation. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
BridgeBio Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.